

## Allergy Therapeutics<sup>PLC</sup>

**Allergy Therapeutics plc**  
("Allergy Therapeutics" or the "Company")

### **Notice of 2025 Annual General Meeting**

**06 January 2026** - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, has today published its Notice of Annual General Meeting following publication of the Annual Report and Accounts for the year ended 30 June 2025 (the "2025 Accounts"). The Notice of Annual General Meeting has been posted to shareholders of the Company (the "Shareholders") today and is available to view on, and download from, the Company's website at <https://www.allergytherapeutics.com/investors/shareholder-services/agm-information/>.

#### **Approval of new appointments to Board**

The Company is seeking shareholder approval to appoint two additional directors to the Board, as detailed below, each of whom brings decades of expertise in their respective fields. The Board believes these appointments will directly support the Group's current explorations of a potential dual primary listing on the Hong Kong Stock Exchange, alongside its existing listing on the London Stock Exchange's AIM market, and the ambition to expand Allergy Therapeutics' presence in Asia and become a global leader in allergy treatments. The proposed appointments of the additional directors remain subject to completion of customary due diligence and will be effective upon receipt of shareholder approval at the Annual General Meeting. A further announcement will be made in due course, as required.

#### **Helge Weiner-Trapness - Executive Director and Chief Strategy Officer**

Until 2025, Mr Weiner-Trapness held the role of Vice Chairman, Global Banking, at HSBC, one of the world's largest financial organisations which is dual-listed on the London Stock Exchange and the Hong Kong Stock Exchange. Prior to this, he was a Founding Partner of Hong Kong-based Quintus Partners, an independent financial advisory firm offering investment banking, strategic advisory and capital raising, particularly in the US and Asia. With earlier, senior positions at Barclays Bank, Asia Pacific Land, JP Morgan Securities and Goldman Sachs, Mr Weiner-Trapness brings more than 30 years of experience across some of the world's biggest investment banks in the US and Asia.

In the newly created role of Chief Strategy Officer, Mr Weiner-Trapness will drive the Group's long-term growth strategy, including corporate development, partnership strategy and portfolio prioritisation, as Allergy Therapeutics advances its next-generation pipeline and explores opportunities to deliver on its global ambitions.

#### **Lawrence Allen Wang - Non-Executive Director**

Lawrence Allen Wang is the Chief Financial Officer of Adicon (HKG: 9860) one of China's leading independent clinical laboratory service providers. Mr Wang led and executed the company's 88 million share financing in 2020, bringing in an international, blue-chip investor syndicate and, in 2023, successfully listed the company on the Hong Kong Stock Exchange. Later that year the company qualified for entry into the Hong Kong Stock Exchange's Stock Connect mutual market access programme, that links the Hong Kong Stock Exchange with Mainland China's two main exchanges. Mr Wang has more than 20 years of healthcare and investment experience. He qualified as a Doctor of Medicine from Boston University School of Medicine in 2003 and has an MBA from MIT Sloan School of Management.

**For further information, please contact:**

**Allergy Therapeutics**

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

**Cavendish Capital Markets Limited (Nominated Adviser and Broker)**

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

**ICR Healthcare**

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

[allergytherapeutics@icrhealthcare.com](mailto:allergytherapeutics@icrhealthcare.com)

**Notes for editors:**

**About Allergy Therapeutics**

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries and branches in nine major European countries and via distribution agreements in an additional four countries. For more information, please see [www.allergytherapeutics.com](http://www.allergytherapeutics.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAFZGGMMKLGVZZ